SAM
Sherman Asset Management Portfolio holdings
AUM
$116M
1-Year Est. Return
17.67%
1 Year Est. Return
+17.67%
AUM
$113M
AUM Growth
+$8.11M
(+7.7%)
Holding
156
Top Buys
| 1 | +$4.26M | |
| 2 | +$1.25M | |
| 3 | +$580K | |
| 4 |
Vanguard ESG US Stock ETF
ESGV
|
+$351K |
| 5 |
Financial Select Sector SPDR Fund
XLF
|
+$338K |
Top Sells
| 1 | +$3.98M | |
| 2 | +$1.35M | |
| 3 | +$1M | |
| 4 |
State Street SPDR S&P Kensho New Economies Composite ETF
KOMP
|
+$457K |
| 5 |
iShares ESG Optimized MSCI USA ETF
SUSA
|
+$391K |
Sector Composition
| 1 | Technology | 9.14% |
| 2 | Consumer Discretionary | 7.46% |
| 3 | Communication Services | 7.31% |
| 4 | Consumer Staples | 2.65% |
| 5 | Financials | 2.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
First Trust NYSE Arca Biotechnology Index Fund
FBT
$1.19B
| – | – |
-302
|
|
||
152
DexCom
DXCM
$21.5B
| – | – |
-28
|
|
||
153
Denali Therapeutics
DNLI
$2.2B
| – | – |
-94
|
|
||
154
Avantor
AVTR
$7.87B
| – | – |
-132
|
|
||
155
Broadcom
AVGO
$1.65T
| – | – |
-23,800
|
|
||
156
Apellis Pharmaceuticals
APLS
$2.44B
| – | – |
-63
|
|